SuperworthPerspective Therapeutics revenue CATX
Sales by quarter and over the last twelve months, from 2010.
- Last 12 months, to Sep 30, 2023
- $8.2M
- Latest quarter, Q3 FY23
- $2.2M
- −25% on a year earlier
- Fiscal year 2022
- $10.8M
- +20% on the year before
Perspective Therapeutics' revenue was $8.2M over the twelve months to Sep 30, 2023, down 26% on a year earlier.
In its latest quarter, Q3 FY23, it was $2.2M, down 25% on the same quarter a year before.
Over the five fiscal years to FY2022 it grew 13% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2022 | $10.8M | +20% |
| FY2022 | $9M | −11% |
| FY2021 | $10.1M | +4% |
| FY2020 | $9.7M | +32% |
| FY2019 | $7.3M | +23% |
| FY2018 | $5.9M | +24% |
| FY2017 | $4.8M | −0% |
| FY2016 | $4.8M | +4% |
| FY2015 | $4.6M | +9% |
| FY2014 | $4.2M | −7% |
| FY2013 | $4.5M | −11% |
| FY2012 | $5.1M | −3% |
| FY2011 | $5.2M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY23 | $2.2M | −25% | $8.2M | |
| Q2 FY23 | $2.1M | −26% | $7.7M | |
| Q1 FY23 | $2.1M | −20% | $8.1M | |
| Q4 FY22 | $1.8M | −32% | $9M | |
| Q2 FY22 | $1.7M | −27% | $9.9M | |
| Q4 FY22 | $2.5M | −8% | $10.8M | |
| Q3 FY22 | $2.9M | +12% | $11M | |
| Q2 FY22 | $2.8M | +19% | $10.7M | |
| Q1 FY22 | $2.6M | +8% | $10.2M | |
| Q4 FY21 | $2.7M | +19% | $10.1M | |
| Q3 FY21 | $2.6M | −10% | $9.6M | |
| Q2 FY21 | $2.4M | +7% | $9.9M |
Against its peers
Companies in Drug Manufacturers - General nearest Perspective Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| CATXPerspective Therapeutics | n/m | |
| NATRNatures Sunshine Products | $492M | +7% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| ARVNArvinas | $316.7M | −15% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| Peer median | $316.7M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Perspective Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.